Literature DB >> 6693062

Effect of ursodeoxycholic acid on biliary bile acid and bile lipid composition in gallstone patients.

A Stiehl, R Raedsch, G Rudolph, S Walker.   

Abstract

In five patients with radiolucent gallstones, the effect of ursodeoxycholic acid (Urso) in doses of 250, 500, 750, 1,000, and 1,250 mg per day on biliary lipid and bile acid composition was studied. Biliary cholesterol decreased from 8.8 +/- 0.8 mole% to 4.4 +/- 0.2 mole% at 500 mg Urso per day (7.1 mg per kg) and to 4.2 +/- 0.3 mole% at 750 mg Urso per day (10.7 mg per kg). Administration of 1,000 or 1,250 mg Urso per day produced no further decrease of biliary cholesterol. The biliary content of phospholipids and total bile acids remained unchanged. During Urso treatment, the relative amounts of glyco-Urso and tauro-Urso in bile increased. Glyco-Urso reached a plateau at 49.1 +/- 2.1% of total bile acids during treatment with 1,000 mg Urso per day, and tauro-Urso increased up to 4.3 +/- 1.5% of total bile acids at 250 mg Urso per day. Simultaneously cholic acid, chenodeoxycholic acid, deoxycholic acid, and lithocholic acid decreased. The data indicate that Urso treatment reduces biliary cholesterol efficiently already at a dose of 500 mg per day; biliary bile acid composition changes up to 1,000 mg Urso per day. Doses greater than 1,000 mg per day produced no additional alterations in bile composition.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6693062     DOI: 10.1002/hep.1840040119

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  2 in total

1.  Liver transplantation in 100 children: Cambridge and King's College Hospital series.

Authors:  A Salt; G Noble-Jamieson; N D Barnes; A P Mowat; K Rolles; N Jamieson; P Johnston; P Friend; R Y Calne
Journal:  BMJ       Date:  1992-02-15

2.  Cholesterol (thermodynamic) activity determinations in bile salt-lecithin-cholesterol systems and cholesterol-rich liquid crystalline mesophase formation.

Authors:  U K Jain; W I Higuchi; C L Liu; P H Lee; N A Mazer
Journal:  Pharm Res       Date:  1992-06       Impact factor: 4.200

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.